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Introduction
Emerging evidence from preclinical studies suggests a potential antitumour effect for metformin, a biguanide derivative commonly prescribed to treat type 2 diabetes, possibly due to the activation of AMP-activated protein kinase, leading to the inhibition of the mTOR signalling pathway [1] . Metformin use has been associated with improved survival in patients with diabetes with breast [2] , colorectal [3] and prostate cancer [4] ; however there are limited data in lung cancer patients. Constitutive mTOR signaling plays an important role in the development of lung cancer and in vitro and animal studies have reported antiproliferative effects [5] and proapoptotic effects [6] , as well as the inhibition of lung tumour growth [7] .
Few epidemiological studies have assessed the influence of metformin on lung cancer-specific outcomes after diagnosis. Some, but not all [8] have reported improvements in progressionfree survival [9] and disease-free survival [10, 11] but these investigations were limited by small sample sizes [8] [9] [10] [11] , drug exposure determined at limited numbers of time-points [8] [9] [10] [11] and a lack of adjustment for important baseline patient characteristics [9] . Other studies have investigated metformin use and overall survival [12] [13] [14] , but these results could reflect mortality from non-cancer causes.
In this population-based study, we investigate for the first time the impact of metformin use, either before or after diagnosis, on lung cancer-specific survival. Secondary analysis investigated the influence of other anti-diabetic medications.
Materials and Methods

Study design
As described previously [15] , we utilised record linkages between the English National Cancer Data Repository (NCDR) and the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) to identify lung cancer patients diagnosed between 1998 and 2009. Office of National Statistics (ONS) mortality data provided deaths up to 2012. We restricted the cohort to those with a prior diagnosis of type 2 diabetes (based on a GP diagnosis of diabetes or at least one anti-diabetic medication prescription). Patients with type 1 diabetes were excluded and were defined as those with a diagnosis of type 1 diabetes in addition to at least one prescription for insulin before their cancer diagnosis. Patients were also excluded if they had a previous cancer (with the exception of non-melanoma skin cancers) or if their diagnosis date preceded CPRD research quality records. Ethical approval for all observational studies conducted using CPRD data has been obtained from a multicentre research ethics committee.
Exposure data
Data on post-diagnostic anti-diabetic medication usage was determined from general practitioner (GP) prescribing records contained within the CPRD according to the British National Formulary (BNF) [16] including metformin, sulfonylureas, insulin or other antidiabetic medications (including thiazolidinediones).
Covariates
The NCDR provided clinical data on tumour histology and receipt of cancer treatments including surgery, chemotherapy and radiotherapy. Information on lifestyle factors before diagnosis including smoking, alcohol and BMI was obtained from CPRD records.
Comorbidities prior to diagnosis were derived from GP records and included those within a recent adaptation of the Charlson Comorbidity index [17] . A measure of deprivation was available from CPRD records [18] . Other medications including low-dose aspirin and statins were determined from GP-prescription records. Haemoglobin A1c (HbA1c) levels in the year prior to diagnosis were obtained from GP records.
Statistical analysis
Statistical analysis for anti-diabetic medication use after diagnosis
The analysis of drug use after diagnosis used Cox regression models to produce unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals (CI) for the association between antidiabetic medication usage and lung cancer-specific mortality. Patients that died in the first 6 months after diagnosis were removed as drug use during this time is unlikely to exert an effect on cancer death. Drug use was treated as time-varying [19] , and was lagged by 6 months to remove prescriptions immediately prior to death (as these may reflect end-of-life care). Doseresponse relationships were investigated for metformin use by increasing number of prescriptions and defined daily doses (DDDs), as defined by the WHO [20] . Sub-group analyses for metformin use and lung cancer mortality were carried out by pre-diagnostic drug use and tumour histology. Separate sensitivity analyses additionally adjusted for smoking and HbA1c level (among individuals with available information) and type 2 diabetes duration (among individuals with at least 5 years of records before diagnosis).
Statistical analysis for anti-diabetic medication use before diagnosis
Cox regression models were utilised to calculate unadjusted and adjusted HRs and 95% CIs for the association between anti-diabetic medication usage in the year prior to diagnosis and lung cancer-specific mortality. Patients with less than 1 year of CPRD records prior to diagnosis were removed. Similarly, dose-response relationships for metformin use were examined.
Sensitivity analyses additionally adjusted for smoking, HbA1c level and type 2 diabetes duration.
Results
Patient cohort
A total of 1,443 lung cancer patients with diabetes were identified. The analysis of anti-diabetic medication use after diagnosis included 533 patients, after 910 patients with less than 6 months follow-up were excluded. The analysis of anti-diabetic medication use before diagnosis included 1,350 patients, after 93 patients with less than 1 year of records prior to diagnosis were excluded. Patient characteristics by metformin use are listed in Table 1 . Users were more likely to be diagnosed more recently, be younger, be obese, to have had surgery and chemotherapy and to be users of statins and other anti-diabetic medications (except insulin).
Some comorbidities were less common in users of metformin after diagnosis, Table 1 .
Association between anti-diabetic medication use after diagnosis and survival
The results for the association between anti-diabetic medication use after diagnosis and survival are presented in Table 2 . Metformin use after diagnosis was weakly associated with a reduction in lung cancer death, however, after adjustment for potential confounders, results attenuated (adjusted HR 0.86, 95% CI 0.68-1.09) and there was no significant dose-response relationship by increasing number of prescriptions or DDDs. In sub-group analyses, results were similar after stratification by pre-diagnostic metformin use (non-users: adjusted HR 0.71, 95% CI 0.45-1.13; users: adjusted HR 0.83, 95% CI 0.41-1.69, p for interaction=0.52) and tumour histology (small cell lung cancer: adjusted HR 0.61, 95% CI 0.23-1.60; non-small cell lung cancer: adjusted HR 0.85, 95% CI 0.63-1.14), p for interaction=0.87). Additional adjustment for other factors did not materially alter effect estimates, including smoking (adjusted HR 0.86, 95% CI 0.68-1.10), HbA1c level (adjusted HR 0.88, 0.68-1.13) and diabetes duration (adjusted HR 0.82, 95% CI 0.62-1.10).
There was no evidence of an association for sulfonylurea or insulin use. There was a suggestion of an increased risk of cancer mortality with the use of other anti-diabetic medication (including thiazolidinediones); but analysis was not significant and based on only 45 users (adjusted HR 1.42, 95% CI 0.94-1.13).
Association between anti-diabetic medication use before diagnosis and survival
No association between metformin use prior to diagnosis and lung cancer-specific mortality was observed and no dose-response association was apparent, Table 2 . The findings remained largely unchanged after additional adjustment for smoking, HbA1c level and type 2 diabetes duration (data not shown). Sulfonylurea, insulin and other anti-diabetic medication use were not associated with cancer-specific mortality, Table 2 .
Discussion
Using population-based data, we observed a 14% non-significant reduction in cancer-specific mortality with metformin use after diagnosis in a large cohort of lung cancer patients with preexisting type 2 diabetes, however this reduction was weak in magnitude and there was no clear evidence of a dose-response association.
No study has investigated the influence of metformin use on cancer-specific survival in a cohort of lung cancer patients. Inconsistent with our findings, two previous studies reported significant reductions in all-cause mortality in users of metformin before [13] or after [14] lung cancer diagnosis. A further study reported a shorter overall survival in pre-diagnostic metformin users compared to non-users [12] . Unlike our investigation, previous studies did not investigate dosedependent relationships [12] [13] [14] and metformin use after diagnosis was time-fixed [14] , thus potentially introducing immortal time bias. Moreover, results from studies investigating allcause mortality could be reflective of non-cancer mortality.
Strengths of this study included an unselected lung cancer cohort and record linkages between
NCDR and ONS data, allowing for robust verification of cancer diagnoses and deaths. Highquality GP prescribing data [21] eliminated any recall bias and allowed for temporal associations to be examined. Furthermore, we provided an inclusive and simultaneous examination of all anti-diabetic medications and risk of lung cancer-specific mortality. The present study is the largest to investigate metformin use and outcomes after lung cancer diagnosis; however, a lack of statistical power in sub-group analyses is possible. Although we did not have information on medication compliance, it is unlikely that this is affecting our results because similar findings were observed in dose-response analyses. We were also unable to adjust for cancer stage, thus potentially introducing residual confounding.
Conclusion
In conclusion, the results from this novel population-based study provide little evidence that metformin use is associated with increased lung cancer survival. Further investigation in larger sample sizes is required to verify these findings.
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